AstraZeneca’s Dapagliflozin gets extended indication approval from DCGI to treat heart failure in… EP News Bureau Jul 25, 2023 The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted…
Dapagliflozin meets primary endpoint in Deliver phase-III trial EP News Bureau May 24, 2022 Reduces risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
